Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A polynucleotide shown by the nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing or by the complementary nucleotide sequence, or a polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide.

2. (Original) A polynucleotide shown by the nucleotide sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 5, in the sequence listing, or by the complementary nucleotide sequence, or a polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 6 in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide.

3. (Original) A polynucleotide containing a polynucleotide shown by the nucleotide sequence set forth in SEQ ID NO: 3, in the sequence listing or by the complementary nucleotide sequence, or a polynucleotide containing a polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 4, in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide, wherein the polynucleotide encodes a protein that accelerates the activation of Cdc42.

4. (Currently amended) A polynucleotide shown by a nucleotide sequence having a homology of at least approximately 70% with the nucleotide sequence of the polynucleotide according to claim 1, ~~or claim 2,~~ wherein the polynucleotide encodes a protein that accelerates

the activation of Cdc42.

5. (Currently amended) A polynucleotide with a mutation or an induced mutation, such as deletion, substitution, or addition of one or more nucleotides in the nucleotide sequence of the polynucleotide according to claim 1 ~~or claim 2~~, wherein the polynucleotide encodes a protein that accelerates the activation of Cdc42.

6. (Currently amended) A polynucleotide that hybridizes to the polynucleotide according to claim 1 ~~or claim 2~~ under stringent conditions, wherein the polynucleotide encodes a protein that accelerates the activation of Cdc42.

7. (Currently amended) A recombinant vector containing the polynucleotide according to ~~any one of claims 1 to 6~~ claim 1.

8. (Original) A transformant that has been transfected with the recombinant vector according to claim 7.

9. (Original) A transformant that has been transfected with the recombinant vector according to claim 7, and a recombinant vector containing a polynucleotide encoding Cdc42.

10. (Original) A protein shown by the amino acid sequence set forth in SEQ ID NO: 2, in the sequence listing.

11. (Original) A protein shown by the amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 6, in the sequence listing.

12. (Currently amended) A protein encoded by the polynucleotide according to ~~any one of claims 3 to 6~~ claim 3.

13. (Currently amended)) A method of producing the protein according to ~~any one of claims 10 to 12~~ claim 10, comprising a step of culturing the transformant ~~according to claim 8 or claim 9~~ that has been transfected with a recombinant vector containing a polynucleotide shown by a

polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide.

14. (Currently amended) An antibody that recognizes the protein according to ~~any one of claims 10 to 12~~ claim 10.

15. (Currently amended) A method of identifying a compound that inhibits the function of the proteins according to ~~any one of claims 10 to 12~~ claim 10, and/or the expression of the polynucleotides shown by a polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide ~~according to any one of claims 1 to 6~~, comprising detecting the presence, absence or change in the function and/or the expression under conditions where the interaction of a compound with the protein and/or the polynucleotide are allowed, and determining whether the compound inhibits the function of the protein and/or the expression of the polynucleotide.

16. (Original) The method according to claim 15, wherein the function of the protein is a function of binding to Cdc42 and/or a function of accelerating the activation of Cdc42.

17. (Currently amended) A method of identifying a compound that inhibits the function of the protein according to ~~any one of claims 10 to 12~~ claim 10 and/or the expression of ~~the~~ a polynucleotide shown by a polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide ~~according to any one of claims 1 to 6~~, comprising using at least one selected from the protein ~~proteins according to any one of claims 10 to 12~~, ~~the polynucleotides~~ a polynucleotide shown by a polynucleotide encoding a protein

shown by the amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide ~~according to any one of claims 1 to 6~~, ~~the~~ a recombinant vector containing said polynucleotide, ~~according to claim 7,~~ ~~the transformants according to claim 8 or claim9~~ a transformant that has been transfectected with the recombinant vector or an ~~and the~~ antibody ~~according to claim 14~~ that recognizes said protein.

18. (Original) The method according to claim 17, wherein the function of the proteins is a function of binding to Cdc42 and/or a function of accelerating the activation of Cdc42.

19. (Currently amended) A method of determining whether a tissue specimen derived from a human stomach tissue is a tissue derived from a human stomach tumor or not, comprising measuring an amount of expression of the polynucleotide according to ~~any one of claims 1 to 6~~ claim 1 in the tissue specimen.

20. (Currently amended) The method according to claim 19, wherein the method determines that the tissue specimen is a tissue derived from a human stomach tumor in the case when the amount of expression of the polynucleotide according to ~~any one of claims 1 to 6~~ claim 1 in the tissue specimen is 4.5 times higher than that in a control tissue derived from normal human stomach tissue.

21. (Currently amended) An agent for preventing and/or treating a stomach tumor, comprising a compound that inhibits the function of the protein according to ~~any one of claims 10 to 12~~ claim 10 and/or a compound that inhibits the expression of the polynucleotide shown by a polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide ~~according to any one of claims 1 to 6~~, as an effective ingredient.

22. (Currently amended) A method of preventing and/or treating a stomach tumor, comprising using a compound that inhibits the function of the protein according to ~~any one of claims 10 to 12~~ claim 10 and/or a compound that inhibits the expression of the polynucleotide shown by a polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide ~~according to any one of claims 1 to 6~~.

23. (Currently amended) A reagent kit containing at least one selected from the protein according to ~~any one of claims 10 to 12~~ claim 10, ~~the~~ a polynucleotide shown by a polynucleotide encoding a protein shown by the amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing, or a polynucleotide shown by the complementary nucleotide sequence of the polynucleotide ~~according to any one of claims 1 to 6, the~~ a recombinant vector containing said polynucleotide ~~according to claim 7, the~~ a transformant that has been transfected with the recombinant vector ~~according to claim 8 or claim 9~~, ~~and the~~ or an antibody ~~according to claim 14~~ that recognizes said protein.